Randomised, double-blind, placebo-controlled dose-effect study of V0114 (2.5, 5, 7.5 and 10 mg) versus mequitazine 10 mg and placebo in the treatment of seasonal allergic rhinitis.
Latest Information Update: 28 Dec 2021
At a glance
- Drugs Levomequitazine (Primary)
- Indications Grass pollen hypersensitivity
- Focus Therapeutic Use
- Sponsors Pierre Fabre
- 24 Dec 2021 This trial has been completed in Czech Republic, according to European Clinical Trials Database record. (14 Aug 2006)
- 24 Dec 2021 Status changed from recruiting to completed.
- 02 Jun 2011 New trial record